daunorubicin has been researched along with abt-199 in 22 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 16 (72.73) | 2.80 |
| Authors | Studies |
|---|---|
| Caldwell, JT; Chu, R; Edwards, H; Ge, Y; Lin, H; Ma, J; Niu, X; Taub, JW; Wang, G; Wang, ZJ; Xiang, S; Xie, C; Zhang, X; Zhao, J | 1 |
| Tiong, IS; Wei, AH | 1 |
| Lancet, JE | 1 |
| Anstee, NS; Bilardi, RA; Cory, S; Ng, AP; Robati, M; Vandenberg, CJ; Xu, Z | 1 |
| DiNardo, C; Guerra, VA; Konopleva, M | 1 |
| DiNardo, CD; Wei, AH | 1 |
| DiNardo, CD; Richard-Carpentier, G | 1 |
| Emadi, A; Estey, E; Gale, RP; Karp, JE; Othus, M | 1 |
| Borthakur, G; Bueso-Ramos, C; Class, CA; Cortes, JE; Daver, N; DiNardo, CD; Do, KA; Garcia-Manero, G; Issa, GC; Jabbour, E; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Khoury, JD; Konopleva, M; Montalban-Bravo, G; Naqvi, K; Patel, K; Pierce, S; Ravandi, F; Routbort, M; Sasaki, K; Short, NJ; Takahashi, K | 1 |
| Andrews, C; Maze, D; Murphy, T; Sibai, H | 1 |
| Estey, EH | 1 |
| Lin, N; Wang, L | 1 |
| Foster, MC; Green, SD; Richardson, DR; Zeidner, JF | 1 |
| Al-Malki, M; Aldoss, I; Ali, H; Aribi, A; Arslan, S; Artz, A; Budde, E; Dadwal, S; Forman, S; Khaled, S; Koller, P; Marcucci, G; Nakamura, R; Ngo, D; Pullarkat, V; Salhotra, A; Sandhu, K; Snyder, DS; Stein, A; Zhang, J | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Konopleva, M; Saxena, K | 1 |
| Chang, LS; Chiou, JT; Huang, CH; Huang, NC; Lee, YC; Shi, YJ; Wang, LJ | 1 |
| Aalikhani, M; Alikhani, M; Bazi, Z; Oladnabi, M; Shamsabadi, F | 1 |
| Chang, LS; Chiou, JT; Huang, CH; Huang, PW; Lee, YC; Wang, LJ; Wu, TH | 1 |
| Babushok, DV; Bruno, XJ; Carroll, MP; Frey, NV; Gill, SI; Hexner, EO; Hwang, WT; Loren, AW; Luger, SM; Maillard, IP; Margolis, D; Martin, ME; Matthews, AH; McCurdy, SR; Paralkar, VR; Perl, AE; Porter, DL; Pratz, KW; Stadtmauer, EA | 1 |
| Ai, J; Arnall, J; Avalos, BR; Boselli, D; Chen, T; Chiad, Z; Chojecki, AL; Copelan, EA; Cruz, A; DiSogra, KY; Grunwald, MR; Karabinos, A; Knight, TG; Patel, R; Ragon, BK; Sanikommu, SR; Shah, NA; Symanowski, J; Verbyla, A | 1 |
| Huang, X; Jin, J; Lou, Y; Ma, L; Mao, L; Ren, Y; Tong, H; Wang, H; Wang, Y; Wu, J; Xu, H; Yang, M; Yao, Y; Ye, X; Zhang, Y; Zhou, Y; Zhu, HH | 1 |
10 review(s) available for daunorubicin and abt-199
| Article | Year |
|---|---|
Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML.
Topics: Aminoglycosides; Aminopyridines; Antibodies, Monoclonal, Humanized; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Liposomes; Molecular Targeted Therapy; Mutation; Proto-Oncogene Proteins c-bcl-2; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Treatment Outcome; Triazines | 2017 |
Is the overall survival for older adults with AML finally improving?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Sulfonamides; Survival Rate | 2018 |
Venetoclax-based therapies for acute myeloid leukemia.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cytarabine; Daunorubicin; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sulfonamides; Triazines | 2019 |
Single-agent and combination biologics in acute myeloid leukemia.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Gemtuzumab; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Neoplasm Proteins; Sulfonamides; Survival Rate | 2019 |
Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?
Topics: Antineoplastic Agents; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Drug Approval; Gemtuzumab; Glycine; Humans; Leukemia, Myeloid, Acute; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Staurosporine; Sulfonamides; United States; United States Food and Drug Administration | 2020 |
Combination treatment with CPX-351 and midostaurin in patients with secondary acute myeloid leukaemia that are FLT3 mutated: three cases and review of literature.
Topics: Aged; Allografts; Anemia, Refractory, with Excess of Blasts; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials, Phase III as Topic; Cytarabine; Daunorubicin; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm, Residual; Neoplasms, Radiation-Induced; Oncogene Proteins, Fusion; Peripheral Blood Stem Cell Transplantation; Point Mutation; Protein Kinase Inhibitors; Pyrazines; Remission Induction; Salvage Therapy; Staurosporine; Sulfonamides | 2020 |
Acute myeloid leukemia: 2021 update on risk-stratification and management.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Risk Assessment; Staurosporine; Sulfonamides; United States | 2020 |
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
Topics: Animals; Antineoplastic Agents; Azacitidine; Benzimidazoles; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Phenylurea Compounds; Prognosis; Sulfonamides | 2021 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
New Treatment Options for Older Patients with Acute Myeloid Leukemia.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Mutation; Patient Selection; Stem Cell Transplantation; Sulfonamides | 2021 |
1 trial(s) available for daunorubicin and abt-199
| Article | Year |
|---|---|
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Neoplasm Proteins; Sulfonamides; Survival Rate | 2020 |
11 other study(ies) available for daunorubicin and abt-199
| Article | Year |
|---|---|
Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells.
Topics: Antineoplastic Agents; Apoptosis; Bcl-2-Like Protein 11; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Protein Stability; Sulfonamides | 2016 |
Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Topics: Animals; Antineoplastic Agents; Biphenyl Compounds; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Humans; Injections, Intravenous; Leukemia, Myeloid, Acute; Mice; Mice, Inbred C57BL; Myeloid Cell Leukemia Sequence 1 Protein; Myeloid-Lymphoid Leukemia Protein; Neoplasms, Experimental; Nitrophenols; Oncogene Proteins, Fusion; Piperazines; Proto-Oncogene Proteins c-bcl-2; Structure-Activity Relationship; Sulfonamides; THP-1 Cells | 2019 |
How I treat acute myeloid leukemia in the era of new drugs.
Topics: Adult; Aged; Aminopyridines; Aniline Compounds; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Female; fms-Like Tyrosine Kinase 3; Glycine; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Male; Molecular Targeted Therapy; Mutation; Prognosis; Pyrazines; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Staurosporine; Sulfonamides; Triazines | 2020 |
Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Disease Progression; Hematopoietic Stem Cell Transplantation; Humans; Immunophenotyping; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Remission Induction; Sulfonamides; Treatment Outcome | 2021 |
Outcome of secondary acute myeloid leukemia treated with hypomethylating agent plus venetoclax (HMA-Ven) or liposomal daunorubicin-cytarabine (CPX-351).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Combined Modality Therapy; Cytarabine; Daunorubicin; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction; Retrospective Studies; Sulfonamides; Treatment Outcome | 2021 |
NOXA-mediated degradation of MCL1 and BCL2L1 causes apoptosis of daunorubicin-treated human acute myeloid leukemia cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cyclic AMP Response Element-Binding Protein; Daunorubicin; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; NADPH Oxidase 4; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Signal Transduction; Sulfonamides; U937 Cells | 2021 |
In silico drug repurposing for the treatment of heart diseases using gene expression data and molecular docking techniques.
Topics: Aminoisobutyric Acids; Aminopterin; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Daunorubicin; Digoxin; Drug Repositioning; Gene Expression; Heart Diseases; Humans; Lactams, Macrocyclic; Leucine; Ligands; Methylergonovine; Molecular Docking Simulation; Morpholines; Proline; Quinoxalines; Sulfonamides | 2021 |
CREB/Sp1-mediated MCL1 expression and NFκB-mediated ABCB1 expression modulate the cytotoxicity of daunorubicin in chronic myeloid leukemia cells.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cyclic AMP Response Element-Binding Protein; Daunorubicin; Drug Synergism; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; NADPH Oxidase 4; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Reactive Oxygen Species; Sp1 Transcription Factor; Sulfonamides | 2022 |
Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia.
Topics: Aged; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Prospective Studies; Quality of Life; Retrospective Studies; Sulfonamides | 2022 |
Outcomes and hospitalization patterns of patients with acute myelogenous leukemia treated with frontline CPX-351 or HMA/venetoclax.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Hospitalization; Humans; Leukemia, Myeloid, Acute; Sulfonamides | 2022 |
Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cytarabine; Daunorubicin; Humans; Leukemia, Myeloid, Acute; Remission Induction; Retrospective Studies | 2023 |